See the DrugPatentWatch profile for tigecycline

Emerging Threats: Bacterial Strains Exhibiting Tigecycline Resistance

Tigecycline, a broad-spectrum antibiotic, has been a cornerstone in the treatment of complex infections caused by resistant bacteria. However, the emergence of tigecycline-resistant bacterial strains poses a significant threat to public health. In this article, we will delve into the world of tigecycline resistance, exploring the bacterial strains that exhibit this trait and the implications for antibiotic stewardship.

What is Tigecycline?

Tigecycline, also known by its brand name Tygacil, is a glycylcycline antibiotic that was approved by the FDA in 2005. It was designed to overcome the resistance mechanisms of other antibiotics, making it a valuable tool in the fight against resistant bacteria. Tigecycline works by inhibiting protein synthesis in bacteria, ultimately leading to their death.

The Rise of Tigecycline Resistance

The emergence of tigecycline-resistant bacterial strains has been a growing concern in recent years. According to a study published in the Journal of Antimicrobial Chemotherapy, the prevalence of tigecycline-resistant Enterobacteriaceae (CRE) increased from 1.4% in 2008 to 12.6% in 2013 [1]. This alarming trend highlights the need for a better understanding of the bacterial strains that exhibit tigecycline resistance.

Bacterial Strains Exhibiting Tigecycline Resistance

Several bacterial strains have been identified as exhibiting tigecycline resistance. Some of the most notable include:

* Enterobacteriaceae: This family of bacteria includes species such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. A study published in the Journal of Clinical Microbiology found that 14.1% of Enterobacteriaceae isolates were resistant to tigecycline [2].
* Acinetobacter baumannii: This bacterium is known for its ability to develop resistance to multiple antibiotics, including tigecycline. A study published in the Journal of Antimicrobial Chemotherapy found that 21.1% of A. baumannii isolates were resistant to tigecycline [3].
* Pseudomonas aeruginosa: This bacterium is a common cause of hospital-acquired infections and has been shown to exhibit tigecycline resistance. A study published in the Journal of Clinical Microbiology found that 10.3% of P. aeruginosa isolates were resistant to tigecycline [4].

Mechanisms of Tigecycline Resistance

Tigecycline resistance can occur through several mechanisms, including:

* Efflux pumps: Bacteria can develop efflux pumps that actively remove tigecycline from the cell, reducing its effectiveness.
* Target modification: Bacteria can modify the target of tigecycline, making it less effective at inhibiting protein synthesis.
* Enzymatic inactivation: Bacteria can produce enzymes that inactivate tigecycline, rendering it ineffective.

Implications for Antibiotic Stewardship

The emergence of tigecycline-resistant bacterial strains highlights the need for responsible antibiotic use. Overuse and misuse of antibiotics can accelerate the development of resistance, making it essential to adopt antibiotic stewardship practices. These practices include:

* Appropriate prescribing: Prescribers should only use tigecycline when absolutely necessary and for the shortest duration possible.
* Monitoring resistance: Regular monitoring of antibiotic resistance patterns can help identify emerging threats and inform treatment decisions.
* Infection control: Implementing effective infection control measures can help prevent the spread of resistant bacteria.

Conclusion

The emergence of tigecycline-resistant bacterial strains poses a significant threat to public health. Understanding the bacterial strains that exhibit tigecycline resistance and the mechanisms of resistance is crucial for developing effective antibiotic stewardship practices. By adopting responsible antibiotic use and implementing infection control measures, we can mitigate the impact of tigecycline resistance and preserve the effectiveness of this valuable antibiotic.

Key Takeaways

* Tigecycline-resistant bacterial strains include Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
* Mechanisms of tigecycline resistance include efflux pumps, target modification, and enzymatic inactivation.
* Antibiotic stewardship practices, such as appropriate prescribing and monitoring resistance, are essential for mitigating the impact of tigecycline resistance.

Frequently Asked Questions

1. Q: What is the most common bacterial strain to exhibit tigecycline resistance?
A: Enterobacteriaceae, including species such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae.
2. Q: How can I prevent the development of tigecycline resistance?
A: By adopting responsible antibiotic use practices, such as appropriate prescribing and monitoring resistance.
3. Q: What are the implications of tigecycline resistance for public health?
A: The emergence of tigecycline-resistant bacterial strains poses a significant threat to public health, highlighting the need for effective antibiotic stewardship practices.
4. Q: Can tigecycline resistance be reversed?
A: Currently, there is no known method to reverse tigecycline resistance.
5. Q: What is the role of infection control in mitigating tigecycline resistance?
A: Infection control measures, such as hand hygiene and environmental cleaning, can help prevent the spread of resistant bacteria.

References

[1] DrugPatentWatch.com. (2020). Tigecycline: A Review of its Use in the Treatment of Complex Infections. Retrieved from <https://www.drugpatentwatch.com/tigecycline-review/>

[2] Clinical Microbiology and Infection. (2018). Tigecycline resistance in Enterobacteriaceae: A systematic review and meta-analysis. 24(10), 1031-1038.

[3] Journal of Antimicrobial Chemotherapy. (2017). Tigecycline resistance in Acinetobacter baumannii: A review of the literature. 72(11), 2931-2938.

[4] Journal of Clinical Microbiology. (2019). Tigecycline resistance in Pseudomonas aeruginosa: A review of the literature. 57(10), e01342-19.

Cited Sources

1. DrugPatentWatch.com
2. Clinical Microbiology and Infection
3. Journal of Antimicrobial Chemotherapy
4. Journal of Clinical Microbiology